Opportunities and Challenges of Developing Peptide Drugs in the Pharmaceutical Industry

  • Waleed Danho
  • Joseph Swistok
  • Wajiha Khan
  • Xin-Jie Chu
  • Adrian Cheung
  • David Fry
  • Hongmao Sun
  • Grazyna Kurylko
  • Leonid Rumennik
  • Joseph Cefalu
  • Gretchen Cefalu
  • Philip Nunn
Part of the Advances in Experimental Medicine and Biology book series (volume 611)

References

  1. 1.
    D&MD publications. Peptides 2006. New Application in Discovery, Manufacturing, and Therapeutics. Sehgal, A., Author. One Research Drive, suite 400A. Wesborough, MA 01581.Google Scholar
  2. 2.
    Giuliano, F., J. Androl 25, 683–691 (2004).Google Scholar
  3. 3.
    MacNeil D. J. et al., Eur. J. Pharmacology, 450, 93–101 (2002).CrossRefGoogle Scholar
  4. 4.
    Danho, W. et al., in Peptides: The Wave of the Future. M. Lebel and R. Houghten (Editors) American Peptide Society, 701–703 (2001).Google Scholar
  5. 5.
    US Patens 6,600.015 and 7,045,591.Google Scholar
  6. 6.
    Martin, W.J. et al., Eur. J. Pharmacology, 454, 71–79 (2002).CrossRefGoogle Scholar
  7. 7.
    Cefalu, G. et al., Presented at Western Pharmacology Socirty Conference (2005).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Waleed Danho
    • 2
  • Joseph Swistok
    • 2
  • Wajiha Khan
    • 2
  • Xin-Jie Chu
    • 2
  • Adrian Cheung
    • 2
  • David Fry
    • 2
  • Hongmao Sun
    • 2
  • Grazyna Kurylko
    • 2
  • Leonid Rumennik
    • 2
  • Joseph Cefalu
    • 1
  • Gretchen Cefalu
    • 1
  • Philip Nunn
    • 1
  1. 1.Department of PharmacologyUniversity of Sherbrooke Medical SchoolSherbrookeCanada
  2. 2.Roche Research CenterHoffmann-La Roche Inc. NutleyNew JerseyUSA
  3. 3.Roche Bioscience, Palo AltoCaliforniaUSA

Personalised recommendations